Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A Phase 2 Multicenter Study to Test the Effects of ALXN2220 on Markers of Disease Severity and the Safety of Re-Treatment in Patients with T… Ended

2025-520506-35-00 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR- 2025-06-30
A Phase 2b to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With ACPA-Positive Rheumatoid Arthritis Ended

2024-515973-82-00 ACPA-Positive Rheumatoid Arthritis 2025-06-23
A clinical study of sotatercept in people with pulmonary arterial hypertension Ended

2024-518687-12-00 Pulmonary Arterial Hypertension (PAH) 2025-06-19
Evaluation of the safety and efficacy of the drug Veonetinib (AL8326) in the post-first treatment of small cell lung cancer, non small cell … Ended

2023-509067-24-01 - Small Cell Lung Cancer (SCLC) patients who need ≥2nd 2025-06-17
Study on efficacy of nintedanib for treatment of epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients - EPISTOP Ended

2024-518886-89-00 Hereditary haemorrhagic telangiectasia 2025-06-16
Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Ended

2024-517868-33-00 NECTIN4 Amplified Advanced Breast Cancer 2025-06-12
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended

2024-516051-40-00 Small Cell Lung Cancer (SCLC) 2025-06-10
PLUG-IN. Phase 2 of pembrolizumab combined with enfortumab vedotin for advanced melanoma patients. Ended

2024-514163-26-00 Advanced Melanoma 2025-06-09
Assessing the safety, tolerability, and effectiveness of crofelemer in people with the intestinal disease Microvillus Inclusion Disease (MVI… Ended

2024-512845-18-00 Microvillous Inclusion Disease (MVID) 2025-06-03
Early recognition of progressive lung fibrosis in systemic rheumatic diseases: a characterization of the pulmonary environment through extra… Ended

2024-516304-42-00 Patients with connective tissue diseases at high risk o 2025-05-30
A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended

2024-518321-15-00 Asthma 2025-05-30
"Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study)… Ended

2024-513511-27-00 HR-negative/HER2-negative resectable stage I TNBC. 2025-05-29
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr… Ended

2024-511754-41-00 idiopathic pulmonary fibrosis 2025-05-29
A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 Ended

2023-509338-21-00 Primary immune thrombocytopenia 2025-05-28
Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended

2024-513307-13-00 Advanced/metastatic solid tumors including gynecologica 2025-05-26
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended

2024-515494-95-00 Moderate to Severe Atopic Dermatitis (AD) 2025-05-26
A clinical study of sotatercept in people with pulmonary hypertension (MK-7962-023) Ended

2024-515773-99-00 Pulmonary Hypertension 2025-05-26
Phase 2 Study of CVN424 Ended

2024-516811-25-00 Parkinson Disease 2025-05-15
A study to investigate the effect and safety of BW-20805 in adult participants with hereditary angioedema Ended

2024-518207-22-00 Hereditary Angioedema 2025-05-15
A clinical study of pembrolizumab and other treatments for non-small cell lung cancer (MK-3475-01G) Ended

2024-515772-12-00 Lung neoplasm malignant (Stage IV Non-small cell lung c 2025-04-18
A research study comparing how well different doses of the medicine NNC0519-0130 can reduce kidney damage in people living with chronic kidn… Ended

2024-510846-15-00 Chronic Kidney Disease, with or without Type 2 diabetes 2025-04-14
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended

2023-507306-13-00 HER2-positive unresectable locally recurrent or metasta 2025-04-13
In vivo biological standardization of Dermatophagoides allergen extracts. Ended

2024-514108-15-01 Allergies 2025-04-11
Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/D… Ended

2024-518519-20-01 moderate/severe allergic rhinitis/rhinoconjunctivitis w 2025-04-10